logo
  

AMD To Sell, Lease-back Its Singapore Facility

Advanced Micro Devices, Inc. (AMD) said Thursday that its Singapore subsidiary, Advanced Micro Devices (Singapore) Pte Ltd., has entered into a conditional put-and-call option agreement to sell and lease-back its Singapore facility located at 508 Chai Chee Lane, Singapore 469032 to HSBC Institutional Trust Services (Singapore) Limited, in its capacity as trustee of Sabana Shari'ah Compliant Industrial Real Estate Investment Trust.

The deal is expected to generate proceeds of about 59 million Singapore dollars, or USD$46 million, net of all fees, which will be reflected in AMD's third quarter 2013 financial statements when reported on October 17.

AMD expects to record a gain of about $16 million in the third quarter of 2013. AMD Singapore will continue its operations in a portion of the Singapore facility and has negotiated a 10-year sub-lease agreement with Sabana REIT with extension options to continue those operations. The sub-lease would be effective upon the close of the sale of the property.

AMD said the sale of its Singapore facility is in keeping with its strategy to reduce investments and capital in non-core parts of the business, including real estate.

AMD launched operations in Singapore in 1984 and remains committed to the site as a vital part of the company's global operations. In 2012, AMD Singapore completed its transformation from a high-volume manufacturing site to an engineering center of excellence and currently employs about 500 people.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, Kraft Heinz Co. (KHC) reaffirmed its adjusted earnings and organic net sales growth guidance for the full-year 2024. For fiscal 2024, the company still projects adjusted earnings in a range of $3.01 to $3.07 per share on organic... While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook. For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from... While reporting financial results for the first quarter on Wednesday, CVS Health (CVS) slashed its earnings and adjusted earnings guidance for the full-year 2024, reflecting the potential for continued elevated medical cost trends in the remainder of 2024. For fiscal 2024, the company now projects...

This week, we feature OJEMDA’s FDA approval, Bristol Myer’s Job cuts, Novo Nordisk’s increased pricing of drugs in US, Incyte’s strategic acquisition, and Ireland’s Alcohol labels.

View More Videos
RELATED NEWS
Follow RTT